Market Drivers

Growing Demand for Personalized Medicine and Gene Therapies

One of the greatest achievements in the health sector today is personalized medicine tailored to the specific genetic configuration of every patient. Synthetic biology is a big part of making this a reality. Through technologies such as gene editing and more, scientists can create individualized DNA synthesis and even create medicines that they can use to deal with the fundamental cause of an illness rather than its symptoms. The major element of this trend is the gene therapy which is simply the way of treating or even curing one-self by repairing or completely replacing the faulty genes. They are gaining popularity in treating the more complex illnesses that proved difficult or even impossible to treat by use of conventional medications; this includes the rare genetic disorders and certain classes of cancer.

Market Restraints

High Development Costs

Synthetic biology industry faces a substantial dilemma in that the cost of developing this technology is enormous and mainly caused by the high cost and sophistication of the technologically advanced systems required. Synthetic biology demands novice tools comprising of genome engineering, DNA and RNA-synthetic DNA and RNA, as well as CRISPR gene editing, as well as the specialized kits and equipment, which are expensive, ranging between hundreds and thousands of dollars. Moreover, it is also associated with the development of much infrastructure, quality control and breaking through technical difficulties such as yield maintenance and contamination, making it quite expensive to work out an invention developed in the laboratory into commercialized production. 

By Type

In 2024, Enzymes Type has market share of 42.00% of market sales with market value of USD 7,249.84 Million.

Enzymes find many biotechnological applications, cutting across production of metabolic pathways, DNA manipulation and protein engineering. The importance of the enzymes in bio fuels, agriculture and pharmaceutical products imparts the need of efficient and specialized biocatalysts. Due to their flexibility, they are essential both as industrial and research material and are a key element in gene editing and synthetic routes. Their market position has also been strengthened through the reduction of costs and enhancement of performance through advancement in production and enzyme engineering technologies. With the current innovation of synthetic biology, it is plausible to think that the use of enzymes in various applications is going to increase.

By End-User

In 2024, Biotechnology and Pharmaceutical Companies end-user has market share of 37.47% of market sales with market value of USD 6,467.58 Million.

Such companies deploy synthetic biology to develop new ways of solving challenging medical issues e.g. gene therapies, monoclonal antibodies and personalized medicine. Big R and D investments have accelerated the development of new biologics and improved drug delivery systems. More so, the leadership of this segment has been even more enhanced by the increased demand in the production of effective vaccines, particularly against the COVID-19 pandemic. The influence of these businesses within the market is expected to continue expanding as long as they continue with the innovation.

By Geography

North America dominates the Synthetic Biology market with estimated market value of USD 7,767.69 Million in 2024, and is expected to reach USD 42,906.19 Million in 2032.

The area is fueled by high levels of investment both through the public and the private sector and among these are huge levels of government efforts and venture capital. The area has a strong research base and has good universities as well as research institutions that accelerate technological innovations. The rising needs in various areas, such as agriculture, healthcare, energy, etc., in using sustainable solutions also promote the creation of synthetic biology applications.

List Of Top Players

• Genscript
• Thermo Fisher Scientific Inc
• Amyris Inc
• Integrated DNA Technologies Inc.
• Illumina, Inc.
• Bota Biosciences Inc.
• Codexis, Inc.
• Creative Biogene.
• Enbiotix, Inc.
• Eurofins Scientific
• Novozymes
• Pareto Bio, Inc.
• Others

Key Industry Developments

• Rice University established the Rice Synthetic Biology Institute in January 2024 to facilitate translational research.
• In December 2023, the Chan Zuckerberg Initiative, University of Washington and the Allen Institute opened the Seattle Hub for Synthetic Biology cellular-recording technologies.
• In July 2023, Sumitomo Chemical Co., Ltd, and Ginkgo Bioworks announced a new program to develop functional chemicals through synthetic biology to build upon their current biomanufacturing collaboration.

Table Of Contents

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. MARKET INTRODUCTION
   2. MARKET DRIVERS
   3. MARKET RESTRAINTS
   4. FUTURE OPPORTUNITIES
   5. MARKET TRENDS
   6. PORTER’S FIVE FORCES ANALYSIS
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Suppliers
      4. Bargaining Power of Buyers
      5. Intensity of Competitive Rivalry
   7. VALUE CHAIN & PROFIT MARGIN ANALYSIS
   8. PRICING ANALYSIS
   9. REGULATORY FRAMEWORK
   10. COVID-19 IMPACT ANALYSIS
   11. PRODUCT LIFE CYCLE ANALYSIS
   12. PESTLE ANALYSIS
   13. MICRO ECONOMIC ANALYSIS
   14. Market Premium Insights (Enterprise license)
       • Consumer Analysis (List of Potential Consumers)
       • Top 10 Country-Wise Import & Export Data (If Applicable)
       • Regulatory Bodies & Authorization Across the Globe
       • Key Conferences & Events: Next Two Years
       • Top Patents for The Market
5. GLOBAL SYNTHETIC BIOLOGY MARKET REVENUE & SHARE ANALYSIS (2023-2032)
   1. By Type
      1. Enzymes
      2. Oligonucleotide/Oligo Pools and Synthetic DNA
      3. Cloning Technologies Kits
      4. Xeno-Nucleic Acids
      5. Others
   2. By Technology 
      1. Enzymes
      2. PCR Technology
      3. Genome Editing Technology
      4. Others
   3. By Application 
      1. Healthcare
      2. Non-healthcare
   4. By End-User 
      1. Biotechnology and Pharmaceutical Companies
      2. Academic and Research Institutes
      3. Others
6. GLOBAL SYNTHETIC BIOLOGY MARKET REVENUE & SHARE ANALYSIS (2023-2032), BY REGION
   1. NORTH AMERICA 
      1. U.S.
      2. Canada
      3. Mexico
   2. EUROPE
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. ASIA PACIFIC 
      1. China
      2. Japan
      3. India
      4. South Korea
      5. Rest of APAC
   4. MIDDLE EAST & AFRICA
      1. GCC
      2. South Africa
      3. Rest of MEA
   5. LATIN AMERICA
      1. Brazil
      2. Argentina
      3. Rest of LATAM

For all the segments and sub-segments, Qualitative as well as Quantitative data will be provided. In Quantitative we provide the historic (2023), base (2024), estimated (2025) and forecasted (2025-2032) market value in USD Million, Share in XX with a CAGR (2025-2032). This data would be provided on a regional as well as country level.

1. COMPETITIVE LANDSCAPE
   1. OVERVIEW
   2. KEY PLAYERS MARKET SHARE ANALYSIS
   3. LIST OF KEY STRATEGIC DEVELOPMENTS 
2. COMPANY PROFILES
   1. Genscript
      1. Company Overview
      2. Company Financial Insights (Total Revenue, Revenue By Business Segments, and By Region)
      3. Product Benchmarking
      4. Key Strategic Developments (Merges & Acquisitions, Partnership /Agreements/Joint Venture, Expansion, New Product Launches, and other developments)
      5. Business Strategic Overview
      6. SWOT Analysis
   2. Thermo Fisher Scientific Inc
   3. Amyris Inc
   4. Integrated DNA Technologies Inc.
   5. Illumina, Inc.
   6. Bota Biosciences Inc.
   7. Codexis, Inc.
   8. Creative Biogene.
   9. Enbiotix, Inc.
   10. Eurofins Scientific
   11. Novozymes
   12. Pareto Bio, Inc.
   13. Others
3. LIST OF SOURCES

DISCLAIMER